CClinicalTrials.gg
Not yet recruitingNCT07438392Updated Mar 2, 2026

Tecar Therapy in Chronic Knee Osteoarthritis

An interventional study of Tecar Therapy and ShamTecar Therapy in Osteearthritis, sponsored by Kirsehir Ahi Evran Universitesi. Not yet recruiting at 1 site in Turkey (Türkiye). Open to participants aged 40 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-03-02.

Sponsored by Kirsehir Ahi Evran Universitesi · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Jul 2026, 3 months ago, but the record still lists the study as not yet recruiting.
Phase
Not applicable
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
40 Years to 75 Years
Sex
All
01

Study summary

This study aimed to investigate the effects of Tecar therapy on pain, physical function, and physical capacity in patients with chronic knee osteoarthritis.

Read the detailed description

Knee osteoarthritis is a degenerative, inflammatory, and chronic joint disease with an increasing incidence and prevalence worldwide. By causing pain, disability, and deterioration in quality of life, it constitutes a significant public health problem globally. Furthermore, the health, social, and economic burdens associated with chronic knee osteoarthritis are expected to increase in the future. For these reasons, and due to the rising incidence of the disease, clinicians are increasingly focusing on novel treatment strategies.

Currently, both surgical and non-surgical treatment modalities are used in the management of chronic knee osteoarthritis. The cornerstone of treatment consists of patient education, exercise, and weight control. Subsequent steps include pharmacological treatments, intra-articular injections, and physical therapy modalities. These modalities include transcutaneous electrical stimulation, therapeutic ultrasound, thermal modalities, laser therapy, extracorporeal shock wave therapy, electromagnetic field therapy, and capacitive and resistive electric transfer (Tecar therapy).

Tecar therapy is an endogenous diathermy modality that operates in the long-wave range using radiofrequency energy of approximately 0.5 MHz to heat the treated tissues. It consists of two electrodes-capacitive and resistive-with a long-wave current generator and multi-frequency sequential emission systems that deliver energy to tissues in two different modes. In the capacitive mode, an insulated electrode with a metal plate is generally used. The electrical charges generated by the radiofrequency generator accumulate near the insulated electrode, which acts as a dielectric surface. This method is used for the treatment of superficial tissues adjacent to the insulated electrode. In the resistive mode, two metal electrodes distribute electrical charges that tend to accumulate near bone, tendon, and connective tissue.

Tecar therapy has been shown to have positive effects on pain and quality of life in many patients with degenerative and inflammatory orthopedic conditions. Among diathermy modalities, Tecar therapy is considered one of the most appropriate and safe methods, as-unlike ultrasound-it has no limitation in terms of treatment area and does not cause excessive heat accumulation between the skin and the electrode .

To the best of our knowledge, there are very few studies investigating the use of Tecar therapy in chronic knee osteoarthritis. Therefore, the aim of this study was to investigate the effects of Tecar therapy on pain, physical function, and physical capacity in patients with chronic knee osteoarthritis.

02

Conditions studied

  • Osteearthritis

Keywords

  • osteoarthritis
  • Radiofrequency Therapy
  • Pain
  • Physical Functional Performance
03

In context

Osteoarthritis

4,398 studies on the registry are indexed under Osteoarthritis; 583 are open to participants now.

This study's planned enrollment of 60 is below the median of 70 across 3,440 interventional studies indexed under Osteoarthritis.

Browse Osteoarthritis studies →

Lead sponsor

Kirsehir Ahi Evran Universitesi is the lead sponsor of 133 studies on the registry; 55 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
40 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Patients with Kellgren-Lawrence stage 2 or 3 knee osteoarthritis
  • Patients with bilateral knee pain for at least 6 weeks
  • Male and female patients aged 40-75
  • Patients who accept and sign the informed consent form

Exclusion criteria

Exclusion Criteria:

  • Those who have received physical therapy for knee pain in the last 6 months
  • Those who have received intraarticular injection treatments such as hyaluronic acid, PRP, or steroids for knee pain in the last 6 months
  • Those who have undergone knee surgery for any reason
  • Those with inflammatory arthritis
  • Those with existing neurological, cognitive, or psychiatric disorders
  • Those with pacemakers
  • Those with a history of malignancy
  • Those with local vascular or sensory impairment
  • Those with local or systemic infections
  • Those with open wounds on the skin
  • Pregnant or breastfeeding
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Investigator, Outcomes assessor)
Enrollment
60 participants (estimated)

Study arms

  • Experimental
    Tecar theraphy

    Conventional physical therapy and Tecar therapy: Conventional physiotherapy will include 15 sessions of TENS (100 Hz frequency, 10-30 mA intensity) and Hotpack therapy for all groups, 5 sessions per week over 3 weeks. A heating pad will be applied to the painful knee area for 20 minutes to provide superficial heat, followed by 20 minutes of TENS at 100 Hz using an HP or Chattanooga device. Simultaneously, all groups will receive knee isometric and Theraband exercise therapy under the supervision of a physiotherapist. This group will also receive TECAR therapy three times a week for three weeks, a total of nine sessions, at 0.5 MHz frequency, in a 5 min CAP + 10 min RES + 5 min CAP mode, administered by an experienced physiotherapist.

    Other: Tecar Therapy · Other: conventional physical therapy

  • Experimental
    Sham tecar theraphy

    Conventional physical therapy and sham Tecar therapy: Conventional physiotherapy will include 15 sessions of TENS (100 Hz frequency, 10-30 mA intensity) and Hotpack therapy for all groups, 5 sessions per week over 3 weeks. A heating pad will be applied to the painful knee area for 20 minutes to provide superficial heat, followed by 20 minutes of TENS at 100 Hz using an HP or Chattanooga device. Simultaneously, all groups will receive knee isometric and Theraband exercise therapy under the supervision of a physiotherapist. This group will also receive TECAR sham therapy three times a week for three weeks, a total of nine sessions, at 0.5 MHz frequency, in a 5 min CAP + 10 min RES + 5 min CAP mode, administered by an experienced physiotherapist. The gel will be applied before the device is activated.

    Other: ShamTecar Therapy · Other: conventional physical therapy

  • Experimental
    conventional physiotherapy

    Conventional FTR: Conventional physical therapy will include 15 sessions of TENS (100 Hz frequency, 10-30 mA intensity) and Hotpack therapy for all groups, 5 sessions per week over 3 weeks. A heating pad will be applied to the painful knee area for 20 minutes to provide superficial heat, followed by 20 minutes of TENS at 100 Hz using an HP or Chattanooga device. Simultaneously, all groups will receive knee isometric and Theraband exercise therapy under the supervision of a physiotherapist.

    Other: conventional physical therapy

Interventions

  • OtherTecar Therapy

    Tecar Therapy and conventional physical therapy

  • OtherShamTecar Therapy

    ShamTecar Therapy and conventional physical therapy

  • Otherconventional physical therapy

    conventional physical therapy

06

What researchers measure

Primary outcomes

  1. Visual Analog Scale

    VAS is a pain rating scale with numbers 0 and 10. Here 0 means 'no pain' and 10 means 'unbearable pain'. The participant will rate the pain according to the scale. Patients' night, rest and activity pain will be evaluated separately.

    Time frame: baseline, 3th week, 12th week

Secondary outcomes

  1. WOMAC

    WOMAC consists of three main subgroups: pain, stiffness, and difficulty performing daily activities. It is a questionnaire with a total of 24 questions. Each question has five alternative answers: none, mild, moderate, severe, and very severe. Scoring is given as follows: pain (maximum 20), stiffness (8), and difficulty performing daily activities (68). High scores indicate worsening symptoms, significant limitations, and insufficient overall health. The Turkish version of the scale was developed by Tüzün et al. in 2005.

    Time frame: baseline, 3th week, 12th week

  2. The 6-minute walk test (6MWT)

    The 6-minute walk test (6MWT) will be used to assess physical capacity. Patients will be asked to walk at their preferred pace for 6 minutes in a 30-meter corridor marked at 3-meter intervals. Rest periods or adjustments to walking speed will be allowed if necessary. The maximum distance covered in 6 minutes along the 30-meter corridor will be measured.

    Time frame: baseline, 3th week, 12th week

07

Study locations

1 site
  • Kırşehir Ahi Evran Üniversitesi
    Kırşehir, Kırşehir, Turkey (Türkiye)
08

References and documents

Publications

  • Coccetta CA, Sale P, Ferrara PE, Specchia A, Maccauro G, Ferriero G, Ronconi G. Effects of capacitive and resistive electric transfer therapy in patients with knee osteoarthritis: a randomized controlled trial. Int J Rehabil Res. 2019 Jun;42(2):106-111. doi: 10.1097/MRR.0000000000000324. PubMed 30362981 ↗
  • Elboim-Gabyzon M, Nahhas F. Laser therapy versus pulsed electromagnetic field therapy as treatment modalities for early knee osteoarthritis: a randomized controlled trial. BMC Geriatr. 2023 Mar 16;23(1):144. doi: 10.1186/s12877-022-03568-5. PubMed 36922781 ↗

Individual participant data

Plan to share: Undecided

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Mar 2, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07438392
Lead sponsor
Kirsehir Ahi Evran Universitesi
Responsible party
Nazife Kapan (Asst. Prof., Kirsehir Ahi Evran Universitesi) — Principal investigator
First posted
Feb 27, 2026
Start date
Apr 1, 2026 (estimated)
Primary completion
Jul 1, 2026 (estimated)
Completion
Aug 1, 2026 (estimated)
Last update
Mar 2, 2026

Study contacts

Nazife K Kapan Tunçer, Asst. Prof.
Contact
nazifekapan@gmail.com
+90 5555839701

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion